About SuperGen
SuperGen is a company based in Dublin (United States) founded in 1991 by David J Bearss, Gregory Swendsen, and Joseph Rubinfeld. SuperGen has raised $3 million across 1 funding round. SuperGen has completed 1 acquisition, including Astex Pharmaceuticals. SuperGen operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Dublin, United States
- Founders David J Bearss, Gregory Swendsen, Joseph Rubinfeld
- SectorsHealthcare
- Website supergen.com
- Social LinkedIn
- Total Equity Funding$3M (USD)
in 1 rounds
- Latest Funding Round$3M (USD), Series A
Oct 2009
- Investments & Acquisitions
Funding Insights of SuperGen
SuperGen has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Series A round of $3 million completed in October 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 1
- Last Round Series A — $3M
- First Round $3M
(Oct 2009)
All 1 funding rounds of SuperGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2009 | $3M | Series A | – | – | – |
People of SuperGen
4 people are tracked at SuperGen (4 in leadership).
| Name | Role | Group |
|---|---|---|
David J Bearss | Co-Founder | Leadership |
Gregory Swendsen | Co-Founder | Leadership |
Joseph Rubinfeld | Co-Founder | Leadership |
James S J Manuso | CEO | Leadership |
Complete people profiles for SuperGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SuperGen
SuperGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Astex Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Speciality pharma comany focused on drug discovery and development with focus on cancer and CNS disorders | astx.com | Pleasanton, United States | 1991 | Jul 2011 | •••• |
Complete acquisition details for SuperGen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of SuperGen
3 dated milestones of SuperGen across 20 years, from founding to its latest funding, stage changes and deals.
- Founded SuperGen is founded.
- Funding First funding round of $3.0M.
- Acquisition Acquires Astex Pharmaceuticals.
Competitors of SuperGen
SuperGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of SuperGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SuperGen
Websites that share an audience with SuperGen (supergen.com).
Websites whose visitors overlap most with SuperGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| durect.com | 100% | 2.1K | #8,779,649 | View details | |
| steinerleisure.com | 80% | – | – | View details | |
| surgecomponents.com | 27% | 1.9K | #6,389,762 | View details | |
| steeltechnologies.com | 27% | 6.8K | #2,480,687 | View details | |
stkr.com | stkr.com | 27% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for SuperGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to SuperGen
10 companies that operate in the same segment as SuperGen (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SuperGen
SuperGen was founded in 1991 and raised its 1st funding round 18 years after it was founded.
SuperGen is headquartered in Dublin, United States.
James S J Manuso is the current CEO of SuperGen.
SuperGen is a funded company, having raised a total of $3M across 1 funding round to date. The company's 1st funding round was a Series A of $3M, raised on Oct 2009.
Developer of cancer therapeutics based on epigenetic targets. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization.The companys products include gemcitabine as a combination first-line therapy for the treatment of advanced pancreatic cancer.
SuperGen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
SuperGen has made 1 acquisition, including Astex Pharmaceuticals.